background image

Entering a new age in cancer drug development

Cancer drug development has accelerated over the last 20 years, yet children with cancer continue to be left behind. Children with cancer in the US first gain access to cutting-edge investigational treatments an average of 6.5 years later than adults. As a result, only 12 new drugs have been approved to treat cancers seen primarily in children in the last 25 years. This disparity in access and innovation is driven by historical misperceptions about safety, regulatory hurdles, complexity of impending pediatric clinical trials, and market sizes.

Day One takes a different approach, encompassing patients of all ages

Inspired by a call to action from the pediatric oncology community, Day One listens to, and acts in service of the needs of patients, their families, and their treating oncologists. Recognizing that many new treatments can benefit both children and adults with cancer based on a tumor’s underlying biology, Day One prioritizes programs that can be rapidly brought to market for both younger and older patients.

We have extensive capabilities and experience with these patients, and our trusted relationships across all key stakeholders in the pediatric medical community enable us to effectively navigate the challenges and nuances of pediatric drug development.

We believe there is a new, better, and faster way to advance novel cancer medicines to improve the lives of patients of all ages.

Our name, Day One, was inspired by the “The Day One Talk.” Keeping the needs of patients and oncologists in mind, we focus our efforts to bring the best medicines to families receiving the life-altering news of a new cancer diagnosis and the need for a treatment plan. Together we can re-envision cancer drug development and redefine what’s possible in the lives of people with cancer – whatever their age – starting from Day One.

Our mission

Inspired by the urgent needs of children with cancer, Day One creatively and intentionally develops new medicines for people of all ages living with cancer.

Leaders with experience, ingenuity, and integrity

Jeremy Bender, PhD, MBA

Jeremy Bender, PhD, MBA

Chief Executive Officer

Jeremy Bender, PhD, MBA

Jeremy Bender, PhD, MBA

Chief Executive Officer

Jeremy Bender, Ph.D., M.B.A. has served as our Chief Executive Officer, President and a member of our board of directors since September 2020. Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, a pharmaceutical company, from March 2018 to September 2020. Prior to that, he was Chief Operating Officer of Tizona Therapeutics from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, he was Vice President of Corporate Development at Allos Therapeutics, a biotechnology company focused on cancer treatments, from January 2006 to September 2012. Dr. Bender began his career in the life sciences practice at Boston Consulting Group, a management consulting company. Dr. Bender also sits on the board of Mereo BioPharma as an independent board member. Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.

Fun Fact

During college Jeremy was a DJ at KZSU radio, a fact his teenage children refuse to accept despite overwhelming supportive evidence.

Samuel Blackman, MD, PhD

Samuel Blackman, MD, PhD

Co-founder and Chief Medical Officer

Samuel Blackman, MD, PhD

Samuel Blackman, MD, PhD

Co-founder and Chief Medical Officer

Samuel Blackman, M.D., Ph.D. is our co-founder and has served as our Chief Medical Officer since November 2018. Prior to co-founding Day One, Dr. Blackman was Head of Clinical Development at Mavupharma, a drug discovery company focused on leveraging the immune system to treat cancer and infectious diseases, from September 2018 to July 2019. Prior to Mavupharma, he was Head of Clinical Development at Silverback Therapeutics, a biotechnology company developing tissue-targeted therapeutics, from August 2016 to September 2018. Prior to Silverback, Dr. Blackman was a senior medical director at Juno Therapeutics, a biotechnology company focused on cancer treatments from June 2014 to August 2016, and before that he held roles of increasing responsibility at Seattle Genetics, Merck, and GlaxoSmithKline. He is a graduate of the pediatric hematology/oncology fellowship program at the Dana Farber Cancer Institute and Children’s Hospital Boston, and the pediatric residency program at Cincinnati Children’s Hospital Medical Center. Dr. Blackman received his B.A. in Philosophy, his M.D. and Ph.D. in Pharmacology from the University of Illinois at Chicago.

Fun Fact

While living in Chicago, Sam supported himself through medical and graduate school as a Spinning™ instructor.

Mike Preigh, PhD

Mike Preigh, PhD

Chief of Technology Operations

Mike Preigh, PhD

Mike Preigh, PhD

Chief of Technology Operations

Mike brings over 25 years of experience in product development and manufacturing to Day One. Prior to joining Day One, he was an independent consultant supporting CMC development for multiple venture backed start-up companies. He spent 10 years at Array BioPharma, where he led a CMC group that successfully filed INDs for 20+ new chemical entities and supported clinical development of multiple marketed drugs including binimetinib and tucatinib. He also spent 12 years at Pfizer in Manufacturing and R&D. He received his PhD in Chemistry from the University of Pittsburgh and his BA Chemistry from Illinois Wesleyan University.

Fun Fact

Mike worked through college as an elementary school playground supervisor, baseball umpire, and waste-water treatment technician among many other jobs.

Lisa Bowers

Lisa Bowers

Chief Commercial Officer

Lisa Bowers

Lisa Bowers

Chief Commercial Officer

Lisa is the Chief Commercial Officer of Day One. She was most recently the CEO and founder of Rhia Ventures, a social venture investment organization focused on reproductive health.  She was also the COO of the Tara Health Foundation and had an extensive career at Genentech/Roche, where she held P&L accountability for Genentech’s $400M+ cystic fibrosis business and was the head of the North American supply chain region, accountable for $20B+ of medicine across the United States and Canada. Prior to these roles, Lisa led Genentech’s patient access services, serving over 100,000 patients annually, and led the company’s strategic marketing function for managed care organizations.  Lisa has been a board observer for Cadence Health and is a member of the board for Planned Parenthood Mar Monte, the largest affiliate in the country.  She earned an English degree from Yale University and a Master of Health Services Administration from the University of Michigan School of Public Health.

Fun Fact

Lisa once opened for Bon Jovi in Vegas.

Charles N. York II

Charles N. York II

Chief Operating and Financial Officer

Charles N. York II

Charles N. York II

Chief Operating and Financial Officer

Charles York II, M.B.A., has served as our Chief Operating Officer and Chief Financial Officer since February 2021. Immediately prior to joining Day One, Mr. York served as Chief Financial Officer and Vice President of Aeglea Biotherapeutics, Inc., a biotechnology company specializing in rare metabolic disease , where he led the investor relations, corporate development, communications, financial planning, accounting, human resources and information technology since September 2015, after joining Aeglea as Vice President, Finance, in July 2014. Prior to joining Aeglea, Mr. York held financial management roles in the life science, pharmaceutical and technology industries and began his career at PricewaterhouseCoopers LLP. Mr. York is a CPA in the state of Arizona and received a B.S. in Accounting from the University of Connecticut and an MBA from the McCombs School of Business at the University of Texas at Austin.

Fun Fact

Davy Chiodin, PharmD

Davy Chiodin, PharmD

Chief Development Officer

Davy Chiodin, PharmD

Davy Chiodin, PharmD

Chief Development Officer

Dr. Davy Chiodin brings to Day One nearly 20 years of pharmaceutical industry experience and 15 years of oncology development experience across tumor types and stages of development. In his role, Davy oversees Regulatory Science, Clinical Operations, Biometrics, Program Management and Quality Assurance. Prior to joining Day One, Davy was at Acerta, a member of the AstraZeneca group, where he led the Regulatory Science and Quality Assurance functions through the acalabrutinib global filings and the build of the AZ hematology franchise. Davy spent more than 10 years at Roche/Genentech, assuming roles of increased responsibility in the Regulatory function in both Europe and the US, including 2 years fully dedicated to the pediatric oncology portfolio. He has remained an active contributor to the pediatric oncology community since then.
Davy received his PharmD from the university of Grenoble, France, and a Master in Regulatory Affairs and Pharmacoeconomics from the universities of Lille and Paris, France.

Fun Fact

Davy was born in the Alps and was put on skis nearly at the same time as he learned to walk.

Jaa Roberson

Jaa Roberson

Chief People Officer

Jaa Roberson

Jaa Roberson

Chief People Officer

Jaa Roberson has 20 years of human resources experience across the biopharma, health insurance, and retail industries. Most recently, she was the head of human resources for Bellicum Pharmaceuticals, a clinical-stage biopharmaceutical company focused on cellular immuno-oncology. Previously, she served as the head of human resources for Achaogen. Before that, she spent six years at Genentech/Roche supporting the oncology, IMPACT, and immunology & ophthalmology commercial business units. Earlier in her career, Ms. Roberson held human resources roles at Blue Shield of CA, Levi Strauss & Company, and Williams-Sonoma. Ms. Roberson earned her Bachelor of Arts from Rice University and her Master of Violin Performance from the San Francisco Conservatory of Music.

Fun Fact

A past proud owner of a purple Honda Rebel motorcycle.

Board of Directors

Julie Grant, MPhil, MBA

Chair

Julie Grant, MPhil, MBA

Chair

Julie Grant is a General Partner at Canaan, a tech and healthcare venture capital fund with $5B assets under management. She primarily leads investments and company formation efforts in biopharmaceuticals. Julie is a co-founder at Day One, was previously CEO, and is chair of the board. Since joining Canaan in 2013, Julie has incubated, financed, and supported investments in multiple new ventures including Nocion, Synthekine, Protagonist (PTGX), Cellular Research (Acquired by Becton Dickinson), Dermira (DERM), Labrys Biologics, CytomX (CTMX), Unchained Labs, Chrono Therapeutics, Genome Medical, Glooko, Vineti, and Truveris. Prior to joining Canaan, Julie worked at Genentech in multiple capacities across development and commercial. She earned a BS in Molecular Biophysics and Chemistry from Yale, an MPhil BioScience Enterprise from Cambridge, and MBA from Stanford.

Dan Becker, MD, PhD

Director

Dan Becker, MD, PhD

Director

Dan Becker is a Partner at Access Biotechnology, the biopharmaceutical investing arm of Access Industries, a privately held US-based industrial group with global strategic investments of $25+ billion. Prior to joining Access, Dan was a Principal at New Leaf Venture Partners, where he played a key role in multiple private and public biopharma investments, and a Principal in the Health Care practice at the Boston Consulting Group, where he led projects across the healthcare sector with an emphasis on biopharma R&D. Dan trained clinically in internal medicine and nephrology at Brigham and Women’s Hospital and Massachusetts General Hospital, and was a Research Fellow at Harvard Medical School. He obtained both his MD and PhD (Cellular and Molecular Biology) degrees from the University of Michigan, and received his BS in Physiology from the University of Illinois at Urbana-Champaign.

Jeremy Bender, PhD, MBA

Director

Jeremy Bender, PhD, MBA

Director

Jeremy Bender is Chief Executive Officer of Day One.  He brings more than 15 years of biopharma leadership experience to the company. Prior to joining Day One, Jeremy was Vice President of Corporate Development at Gilead Sciences. In that role he led the team responsible for Gilead’s acquisitions, partnerships, and equity investments and oversaw more than 40 transactions exceeding $10 billion in upfront deal value, including the acquisition of Forty Seven, Inc.  Through prior roles as COO of Tizona Therapeutics, CBO of Sutro Biopharma and Vice President of Corporate Development at Allos Therapeutics, Jeremy has extensive experience building innovative biopharma companies and leading them through program and portfolio selection, product development and commercialization, and strategic business development and financing transactions.  Jeremy began his career in the life sciences practice at Boston Consulting Group. He holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.  He is a former Board member of Vaxcyte (fka SutroVax).

Scott Garland

Director

Scott Garland

Director

Scott Garland is the chief executive officer of PACT Pharma, an immuno-oncology company focused on developing neoantigen targeted T-cell therapies for solid tumors. Prior to PACT, Mr. Garland served as president and chief executive officer of Portola Pharmaceuticals, where he led the company through the commercial launch of Andexxa® and a successful acquisition by Alexion. Before joining Portola, Mr. Garland was at Relypsa, where he served as chief commercial officer, and then as president of the U.S. organization after Relypsa’s acquisition by Vifor Pharma. Prior to Relypsa, Mr. Garland was chief commercial officer at Exelixis where he led the launch of cabozantinib. Mr. Garland has held numerous other commercial leadership roles at Genentech, Amgen and Merck, including leading the commercial franchises for two multi-billion dollar therapies – Avastin® and Rituxan®. He also serves as a board member for Calithera Biosciences. Mr. Garland received a Bachelor of Science degree from California Polytechnic State University-San Luis Obispo and a master’s degree in Business Administration from the Fuqua School of Business at Duke University.

Michael Gladstone

Director

Michael Gladstone

Director

Michael Gladstone is a Partner at Atlas Venture, where he builds new therapeutics companies, primarily in the areas of oncology and immunology.

Michael contributed to launching several Atlas-originated companies, including Padlock Therapeutics (acquired by BMS), Surface Oncology (NASDAQ: SURF), and IFM Therapeutics Inc (acquired by BMS; and its spinout IFM Tre acquired by Novartis). He has served as a board member or observer for IFM Therapeutics LLC, Indalo Therapeutics, Akrevia Therapeutics, AvroBio (NASDAQ: AVRO), Akero (NASDAQ: AKRO), Delinia (acquired by Celgene), and Replimune (NASDAQ: REPL).

Prior to joining Atlas in 2012, Michael worked at L.E.K. Consulting and previously, he conducted HIV vaccine research in the Viral Pathogenesis department of Beth Israel Deaconess Medical Center.

Michael serves as an advisor to several organizations, including as member of the Corporate Advisory Committee for National Tay Sachs and Allied Diseases, a national organization focused on funding research, promoting awareness, and supporting families affected by Tay-Sachs and related genetic diseases.

Natalie Holles

Director

Natalie Holles

Director

Natalie currently serves as Chief Executive Officer (CEO) of Third Harmonic Bio. She has more than 20 years of executive leadership, business development, corporate strategy, and commercial experience gained in a range of therapeutic areas. Prior to Third Harmonic, Natalie served as President and CEO of Audentes, an Astellas company. She joined the company as Senior Vice President and Chief Operating Officer in August 2015 and was subsequently promoted to President and Chief Operating Officer in May 2018, and then to President and CEO in January 2020. Prior to joining Audentes, Natalie served as Senior Vice President, Corporate Development at Hyperion Therapeutics, Inc. (acquired by Horizon Pharma in 2015). Before that, she provided executive-level strategy and business development advisory services to a number of privately-held biopharmaceutical companies. Earlier in her career, Natalie served as Vice President, Business Development at KAI Pharmaceuticals, Inc. (acquired by Amgen in 2012) and held corporate development and commercial roles at InterMune, Inc. (acquired by Roche in 2014) and Genentech, Inc.

Natalie holds an M.A. in molecular, cellular and developmental biology from the University of Colorado, Boulder, where she was a Howard Hughes Medical Institute predoctoral fellow, and an A.B. in human biology from Stanford University.

John A. Josey, PhD, MBA

Director

John A. Josey, PhD, MBA

Director

John Josey is a Venture Partner at The Column Group. Previously he served as the President, Chief Executive Officer and a member of the Board of Directors of Peloton Therapeutics, Inc., from 2013 until its acquisition by Merck in 2019. He joined Peloton in 2011 as the first employee in the role of President and Chief Scientific Officer. For over thirteen years, Dr. Josey was employed at Array BioPharma Inc., a company that he helped to build as a member of the founding management team. There he rose to Vice President of Discovery Chemistry. Dr. Josey’s previous experience also includes Amgen, Inc. and the Glaxo Research Institute. He received a BS degree in chemistry from Colorado State University, a PhD in organic chemistry from The University of Texas at Austin, and an MBA from the University of Colorado. He was a Damon Runyon-Walter Winchell Postdoctoral Fellow at the California Institute of Technology. Dr. Josey is currently an adjunct faculty member of the Department of Biochemistry at The University of Texas Southwestern Medical Center.

John currently serves on the Board of Directors for VHL Alliance, Circle Pharma, Inc. (Chair), Nura Bio, and Day One Biopharmaceuticals.

Saira Ramasastry, MS, MPhil

Director

Saira Ramasastry, MS, MPhil

Director

Ms. Ramasastry is the managing partner of Life Sciences Advisory, LLC, an independent firm that she founded to provide strategic advice and business development solutions for life science companies. Prior to founding Life Sciences Advisory, Ms. Ramasastry spent 10 years as an investment banker with Merrill Lynch & Company, where she helped establish the biotechnology practice and advised on mergers and acquisitions, and strategic and capital markets transactions. Previously, she served as a financial analyst in mergers and acquisitions group at Wasserstein Perella & Co., an investment banking firm. Ms. Ramasastry currently serves on the board of directors for Vir Biotechnology Inc., Akouos, Inc., Glenmark Pharmaceuticals Ltd., and Sangamo Therapeutics, Inc., and is also a health innovator fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. Ms. Ramasastry holds a B.A. in economics and an M.S. in management science and engineering from Stanford University, as well as an M. Phil. in management studies from the University of Cambridge.

Resources

May 2019

Timing of first-in-child trials of FDA-approved oncology drugs

Read more...

October 2016

Enrolling Adolescents in Disease/Target-Appropriate Adult Oncology Clinical Trials of Investigational Agents

Read more...

February 2004

The Day One Talk

Read more...

Contact us

Address:

Day One Biopharmaceuticals
395 Oyster Point Blvd., Suite 217
South San Francisco, CA 94080

Telephone:

1-650-484-0899